Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

NCT ID: NCT01428973

Last Updated: 2024-05-09

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2024-12-31

Brief Summary

The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).

The immunosuppressive regimens will consist of: Tacrolimus plus Mycophenolate Mofetil or Tacrolimus plus Sirolimus. Before grafting patients will undergo a reduced-intensity conditioning with Fludarabine/total body irradiation (TBI) or Fludarabine/Busulfan/anti-thymoglobuline. Following the interim analysis of October 2014, the protocol has been amended to allow inclusion only after Flu-TBI conditioning. The hypothesis is that the Tacrolimus plus Sirolimus regimen will be associated with better progression-free survival due to a lower incidence of relapse/progression.

Conditions

Graft-Versus-Host Disease; Hematological Malignancies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Arm 1

GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.

Group Type: ACTIVE_COMPARATOR

Mycophenolate mofetil

Intervention Type: DRUG

Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.

Arm 2

GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD

Group Type: EXPERIMENTAL

Sirolimus

Intervention Type: DRUG

Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.

Interventions

Mycophenolate mofetil

Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.

Intervention Type: DRUG

Sirolimus

Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.

Intervention Type: DRUG

Other Intervention Names

CellCept; Rapamune

Eligibility Criteria

Inclusion Criteria

1. Hematological malignancies confirmed histologically and not rapidly progressing:

• Acute myeloid leukemia (AML) in complete remission (CR) (defined as ≤ 5% marrow blasts and absence of blasts in the peripheral blood);
• Myelodysplastic syndromes (MDS) with ≤ 5% marrow blasts and absence of blasts in the peripheral blood;
• Chronic myeloid leukemia (CML) in chronic phase (CP);
• Myeloproliferative neoplasms not in blast crisis and not with extensive marrow fibrosis;
• Acute lymphoid leukemia (ALL)in CR;
• Multiple myeloma not rapidly progressing;
• chronic lymphocytic leukemia (CLL);
• Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);
• Hodgkin's disease with chemosensitive disease;

2. 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.

3. Clinical situations:

1. Theoretical indication for a standard allotransplant, but not feasible because:

• Age > 50 yrs;
• Unacceptable end organ performance;
• At the physician's decision;
• Patient's refusal.

2. Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.

• Male or female; fertile patients must use a reliable contraception method;
• Age ≤ 75 yrs (children of any age are allowed in the protocol);
• Informed consent given by patient or his/her guardian if of minor age.

• HIV positive;
• Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before nonmyeloablative hematopoietic cell transplantation (HCT);
• Life expectancy severely limited by disease other than malignancy;
• Administration of cytotoxic agent(s) for "cytoreduction" within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate);
• CNS involvement with disease refractory to intrathecal chemotherapy;
• Terminal organ failure, except for renal failure (dialysis acceptable)

1. Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia, uncontrolled hypertension;

2. Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen;

3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease;

• Uncontrolled infection;
• Karnofsky Performance Score <70%;
• Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;
• Patient is a female who is pregnant or breastfeeding;
• Any condition precluding the use of sirolimus or MMF;
• One HLA mismatch with peripheral blood stem cells (PBSC) fit to/willing to donate.

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AZ Sint-Jan AV

OTHER

Sponsor Role: collaborator

Ziekenhuis Netwerk Antwerpen (ZNA)

OTHER

Sponsor Role: collaborator

Jules Bordet Institute

OTHER

Sponsor Role: collaborator

University Hospital, Gasthuisberg

OTHER

Sponsor Role: collaborator

AZ-VUB

OTHER

Sponsor Role: collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role: collaborator

University Hospital, Antwerp

OTHER

Sponsor Role: collaborator

Cliniques Universitaires de Mont-Godinne

UNKNOWN

Sponsor Role: collaborator

Hospital de Jolimont

UNKNOWN

Sponsor Role: collaborator

University Hospital, Ghent

OTHER

Sponsor Role: collaborator

AZ Delta

OTHER

Sponsor Role: collaborator

University of Liege

OTHER

Sponsor Role: lead

Responsible Party

Yves Beguin

Prof

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Frédéric Baron, MD; PhD

Role: PRINCIPAL_INVESTIGATOR

University of Liege

Locations

Ziekenhuis Netwerk Antwerpen (ZNA)

Antwerp, Antwerpen, Belgium

University Hospital, Antwerp

Edegem, Antwerp, Belgium

Jules Bordet Institute

Brussels, Brabant, Belgium

AZ VUB Jette

Brussels, Brussels Region Capital, Belgium

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brussels, Brussels Region Capital, Belgium

Queen Fabiola Children's University Hospital

Brussels, Brussels, Region Capital, Belgium

University Hospital, Gasthuisberg

Leuven, Flamish Brabant, Belgium

UZ Gent

Ghent, Flanders Ost, Belgium

Jolimont Hospital Haine Saint Paul

Haine St-Paul, Hainaut, Belgium

Cliniques Universitaires de Mont-Godinne

Yvoir, Namur, Belgium

AZ Sint-Jan AV

Bruges, West Flanders, Belgium

H.-Hart Hospital Roeselare-Menen

Roeselare, Western Flanders, Belgium

CHU Sart Tilman

Liège, , Belgium

Countries

Belgium

Other Identifiers

TJB1016P1

Identifier Type: -

Identifier Source: org_study_id